Biotech Braces for Busy Summer as 2019 M&A Volume Heats Up

Biotech Braces for Busy Summer as 2019 M&A Volume Heats Up

Publication date: Jul 04, 2019

(Bloomberg) — Investors may be digesting a deal from Bristol-Myers Squibb Co. for Celgene Corp. and getting their teeth into AbbVie Inc. ‘s bid for Allergan Plc, but there are plenty of other large-cap biotechs and pharma still hungry for action.

Jefferies analyst Michael Yee found that the shares of half of all biotechs that didn’t get bought underperformed in the months that followed a new drug launch.

Further reading: Slow Start to 2019 M&A Gathers Force With June’s Flood of Deals Highlights from biotech calendars for the second half: Amgen: A court decision or settlement on Amgen’s dispute with Sandoz over patents for its top-selling arthritis drug Enbrel.

Amarin Corp. : A Food and Drug Administration decision on Sept. 28 to update the label for the heart pill Vascepa will be -the gatekeeper for M&A,” Roth analyst Yasmeen Rahimi said. AnaptysBio Inc: Investors are waiting for results for etokimab in atopic dermatitis; shares may rise up to 60% on positive results, JPMorgan analyst Anupam Rama predicted last month. Enanta Pharmaceuticals Inc: Initial results from a NASH study expected in the third quarter. Gilead Sciences: Results evaluating NASH combinations expected to readout in the fourth quarter and may determine the biotech’s direction in the liver disease after a recent failure. GlycoMimetics Inc: Results from a study of Pfizer Inc-partnered rivipansel for sickle-cell-related symptoms.

Pfizer called out the drug as a potential blockbusterMirati Therapeutics Inc: The stock has been breaking records since results from an Amgen study, viewed as a sign that Mirati’s cancer drug may work even better when the small-cap reveals clinical data. Sage Therapeutics Inc: Results in bipolar disorder patients with major depression will be closely watched by investors. Reata Pharmaceuticals Inc: Data from a study of bardoxolone in patients with Alport syndrome, and another study of omaveloxolone in Friedreich’s ataxia. WaVe Life Sciences Ltd: Two readouts expected for Wave, one in Duchenne muscular dystrophy and another in Huntington’s disease. Vertex: Approval for Vertex’s triple combination pill for cystic fibrosis expected this year, although that could slip into 2020, Young said.

Concepts Keywords
AbbVie Biotech catalysts
Allergan Etokimab atopic dermatitis
Alport Syndrome Depression
Amgen Life sciences
Arthritis Biotechnology
Ataxia Companies
Atopic Dermatitis Specialty drugs
Big Pharma Pfizer
Biogen Etanercept
Biotech Gilead Sciences
Bipolar Disorder Biogen
Bloomberg Sanofi
Bolt Amgen
Bristol Myers Squibb
Cantor Fitzgerald
Cap
Caps
Catalyst
Catalysts
Celgene
Cystic Fibrosis
Depression
Duchenne Muscular Dystrophy
Eli Lilly
Enbrel
Gatekeeper
Gilead
Gilead Sciences
JPMorgan
Large Cap
Liver
Merck
Novartis
Patent
Pfizer
Pharma
Portfolio Manager
Rama
Sandoz
Sanofi
Sickle Cell
Sleep
Small Cap
Wildcard

Semantics

Type Source Name
disease MESH cystic fibrosis
disease DOID Duchenne muscular dystrophy
disease MESH Duchenne muscular dystrophy
gene UNIPROT WASF1
drug DRUGBANK Omaveloxolone
disease DOID Alport syndrome
disease MESH Alport syndrome
drug DRUGBANK Bardoxolone
disease MESH depression
disease DOID bipolar disorder
disease MESH bipolar disorder
gene UNIPROT SAGE1
drug DRUGBANK Tropicamide
disease DOID cancer
disease MESH cancer
drug DRUGBANK Rivipansel
disease DOID liver disease
disease MESH liver disease
disease DOID atopic dermatitis
disease MESH atopic dermatitis
gene UNIPROT ELOVL6
gene UNIPROT FANCE
disease MESH arthritis
disease DOID arthritis
disease DOID cystic fibrosis
gene UNIPROT SLC6A2
gene UNIPROT EPHB1
gene UNIPROT ELK3
drug DRUGBANK Coenzyme M
disease DOID face
gene UNIPROT CAPS
gene UNIPROT CADPS
drug DRUGBANK Minaprine
gene UNIPROT FURIN
gene UNIPROT FBXW7
gene UNIPROT BID
gene UNIPROT HSPG2
gene UNIPROT LARGE1
gene UNIPROT CAP1
gene UNIPROT LNPEP
gene UNIPROT HACD1
gene UNIPROT BRD4
gene UNIPROT SORBS1
gene UNIPROT SERPINB6
gene UNIPROT THOP1
gene UNIPROT CFLAR
disease MESH growth

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *